DOXY

Doxycycline 50 mg and 100 mg Tablets

Name of the Medicine

DOXY-100 and DOXY-50

Doxycycline 50 mg and 100 mg tablets.

Description

Doxycycline is a broad spectrum antibiotic. Doxycycline is available as the monohydrate or as the hydrochloride hemiethanolate also called the hyclate. The molecular formula and weight is C\textsubscript{22}H\textsubscript{24}N\textsubscript{2}O\textsubscript{8}, and 444.44 respectively.

The structural formula is:

![Structural formula of Doxycycline](image)

The tablets contain as excipients: microcrystalline cellulose, magnesium stearate, silicon dioxide and maize starch and Opadry White.

Pharmacology

Mechanism of Action
Doxycycline is a broad-spectrum antibiotic that is primarily bacteriostatic. It is thought to exert its antimicrobial effect by inhibition of protein synthesis. It prevents the binding of amino-acyl-tRNA to the messenger RNA-30S ribosomal subunit. The binding of fMet-tRNA is especially sensitive. As a result initiation, and therefore polyribosome formation, are blocked. Doxycycline inhibits only rapidly multiplying organisms.

Pharmacokinetics

Absorption
Doxycycline is virtually completely absorbed after oral administration of either tablets and the absorption is not notably influenced by the ingestion of food or milk.
Distribution
Peak serum levels of approximately 2.6 mcg/ml are achieved at 2 hours following a 200 mg tablet dose. Doxycycline diffuses readily into most body tissues, fluid and/or cavities and the volume of distribution has been measured as 0.7 L/kg. Plasma protein binding is variable.

Elimination
Doxycycline is concentrated by the liver in the bile. It is also excreted in the urine as the unchanged medicine in high concentration. The serum half-life of doxycycline ranges from 18-22 hours and this is not altered by severe renal failure, haemodialysis, age or hepatic failure.

Indications
Doxycycline is indicated in the treatment of uncomplicated chest, urethral, endocervical or rectal infections in adults caused by susceptible organisms (see below) as shown by culture and sensitivity testing. It may also be a useful adjunct to amoebicides in acute intestinal amoebiasis and has a place as adjunctive therapy in severe acne. Doxycycline is active against the following organisms:
- Rickettsiae: rocky mountain spotted
- Fever, typhus fever and the typhus group, Q fever, rickettsial pox, and tick fevers
- Mycoplasma pneumoniae
- Agents of lymphogranuloma venereum and granuloma inguinale
- The spirochetal agent of relapsing fever (Borrelia recurrentis)
- Chlamydia trachomatis
- Haemophilus ducreyi (chancroid)
- Pasteurella pestis, and Pasteurella tularensis, Bartonella bacilliformis, Bacteroids species, Vibrio comma and Vibrio fetus and Brucella species (in conjunction with an aminoglycoside).

Doxycycline may be active against the following organisms although this should be confirmed by culture and sensitivity testing since many strains are resistant.
- Neisseria gonorrhoeae
- Escherichia coli
- Enterobacter aerogenes
- Shigella species
- Mima species and Herellea species
- Haemophilis influenzae species
- Klebsiella species
- Streptococcus species
- Streptococcus pneumoniae
- Staphylococcus aureus in respiratory, skin or soft tissue infection.

When penicillin is contraindicated, doxycycline is an alternative medicine in the treatment of infections due to:
• Treponema pallidum and Treponema pertenue (syphilus and yaws)
• Listeria monocytogenes
• Clostridium species
• Bacillus anthracis
• Fusobacterium fusiforme (Vincent's infection)
• Actinomyces species.

**Contraindications**

• Hypersensitivity to doxycycline, or any other ingredient in DOXY tablets.
• Children under 12 years of age The use of drugs of the tetracycline class, including doxycycline, during tooth development may cause permanent discolouration of the teeth (yellow-grey-brown). This adverse reaction is more common during long term use of the medication but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported.
• Pregnancy. Tetracyclines given during pregnancy affect teeth and skeletal development.
• Nursing mothers. Tetracyclines are excreted into milk and affect teeth and skeletal development.

**Precautions**

**Increased Intracranial pressure**
The use of tetracyclines in infants, even in the usual therapeutic doses, may cause increased intracranial pressure and bulging of the fontanelles. Discontinuation of therapy results in prompt return of the pressure to normal.

**Clostridium difficile associated diarrhoea (CDAD) and antibiotic associated pseudomembranous colitis**

_Clostridium difficile_ associated diarrhoea (CDAD) and antibiotic associated pseudomembranous colitis have been reported with nearly all antibacterial agents including doxycycline, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of _C. difficile_ and _C. difficile_ produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of _C. difficile_ cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against _Clostridium difficile_ should be considered. Fluids, electrolytes and protein replacement should be provided when indicated. Drugs which delay peristalsis, e.g. opiates and diphenoxylate with atropine may prolong and/or worsen the condition and should not be used.
**Gastrointestinal irritation**

Rarely, oesophagitis and oesophageal ulceration have been reported in patients receiving doxycycline tablets. Most of these patients took medication immediately before going to bed. Administration of adequate amounts of fluid with the tablets is recommended to reduce the risk of oesophageal irritation and ulceration, and late evening ingestion of the dose should be avoided.

To reduce the possibility of gastric irritation, it is recommended that doxycycline be given with food or milk. The absorption of doxycycline is not markedly influenced by simultaneous ingestion of food or milk.

**Other considerations**

In venereal disease when coexistent syphilis is suspected, proper diagnostic measures including a dark field examination should be done before treatment is started and the blood serology repeated monthly for at least four months.

In long term therapy, periodic laboratory evaluation of organ systems, including haematopoietic, renal and hepatic studies should be performed.

If doxycycline is used to treat infections due to group A beta-haemolytic streptococci, treatment should continue for at least 10 days.

Abnormal hepatic function has been reported rarely and has been caused by both oral and parenteral administration of tetracyclines, including doxycycline.

As with other tetracyclines, doxycycline forms a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline. This reaction was shown to be reversible when the medicine was discontinued.

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Treatment should be discontinued at the first evidence of skin erythema.

The use of DOXY may occasionally result in overgrowth of nonsusceptible organisms. If a resistant organism appears, the antibiotic should be discontinued and appropriate therapy instituted. In long term therapy, because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anti-coagulant therapy may require downward adjustment of their anti-coagulant dosage.

**Effects on ability to drive and use machines**

The effect of doxycycline on the ability to drive or operate heavy machinery has not been studied. There is no evidence to suggest that doxycycline may affect these abilities.

**Use in Pregnancy**

Results of animal studies indicate that tetracyclines cross the placenta, are found in foetal tissues and have toxic effects on the developing foetus manifested by retardation of skeletal development. The importance of this in humans is not known, however, DOXY should not be used in pregnant women unless the benefit outweighs the risk.
Use in Lactation
DOXY has been found in the milk of lactating women it should not be used in nursing mothers.

Carcinogenicity
Animal studies conducted in rats and mice have not provided conclusive evidence that tetracyclines may be carcinogenic or that they impair fertility. In two mammalian cell lines, positive responses for mutagenicity occurred at concentrations of 60 and 10 mcg/ml respectively. In humans no association between tetracyclines and these effects have been made.

Interactions

DOXY may interfere with the bactericidal effect of penicillins and vice versa.

Anticoagulants
There have been reports of prolonged prothrombin time in patients taking warfarin and doxycycline. Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Methoxyflurane
The concurrent use of tetracyclines and methoxyflurane has been reported to result in fatal renal toxicity.

Oral contraceptives
There have been anecdotal reports that concurrent use of tetracyclines may render oral contraceptives less effective.

Antacids and Iron preparations
Antacids containing aluminium, calcium or magnesium, or other medications containing these cations; bismuth salts; and preparations containing iron impair absorption and should not be given to patients taking doxycycline.

Medicines reducing doxycycline concentrations
Plasma levels of doxycycline are reduced by the ingestion of alcohol or the administration of barbiturates, anticonvulsants (phenytoin, carbamazepine), disodium hydrogen edetate, sodium bicarbonate, sodium lactate, acetazolamide and ethoxzolamide.

Adverse effects

More Common Reactions
Skin and subcutaneous tissue: Photosensitive skin reactions (see Warnings and Precautions), erythematous rash, maculopapular rash, morbilliform rash, pustular rash, urticaria, photonycholysis and discoulouration of the nails.
**Gastrointestinal**: Nausea, anorexia, vomiting, dysphagia, diarrhoea, oesophagitis, oesophageal ulceration, abdominal pain, glossitis, black hairy tongue.

**Hypersensitivity reactions**: Urticaria, exacerbation of systemic lupus erythematosus.

**Hepatic**: Cholestatic hepatitis, fatty liver degeneration.

**Renal**: Dose related increase in serum urea.

**Musculoskeletal**: Tooth discolouration, enamel hypoplasia.

**Others**: Bulging fontanelles have been reported in young infants following full therapeutic dosage. The sign disappeared rapidly when the drug was discontinued.

When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discolouration of thyroid glands. No abnormalities of thyroid function studies are known to occur.

**Less Common Reactions**

**Gastrointestinal**: Enterocolitis (see Warnings and Precautions), inflammatory lesions (with monilial overgrowth) in the anogenital region; dyspepsia and pseudomembranous colitis (see Warnings and Precautions); C. difficile diarrhoea.

**Hepatic**: Abnormal hepatic function has been reported rarely (< 1 in 1000), hepatotoxicity.

**Skin and subcutaneous tissue**: Exfoliative dermatitis; Stevens-Johnson syndrome, Toxic Epidermal Necrolysis (TEN).

**Musculoskeletal**: Arthralgia; myalgia.

**Renal**: Acute renal failure.

**Hypersensitivity reactions**: Angioneurotic oedema, anaphylaxis, anaphylactic shock, anaphylactic reaction, anaphylactoid purpura, serum sickness, pericarditis, hypotension, dyspnoea, peripheral oedema, tachycardia, erythema multiforme.

**Blood and lymphatic system**: Leucopenia, thrombocytopenia purpura, increase in prothrombin time, haemolytic anaemia, eosinophilia.

**Nervous system**: Flushing, malaise, headache, confusion, taste loss, stupor, hypoaesthesia, paraesthesia, somnolence, benign intracranial hypertension in adults, increased intracranial pressure in infants.

**Eye**: Conjunctivitis, periorbital oedema.

**Ear**: Tinnitus.

**Psychiatric**: Depression, anxiety, hallucination.

**Respiratory**: Bronchospasm.
**Dosage and Administration**

The usual dose in adults is 200 mg on the first day of treatment followed by a maintenance dose of 100 mg/day. This may be given as either a single dose or divided doses administered every 12 hours.

In the management of more severe infections 200 mg daily should be given throughout the treatment period. Therapy should be continued at least 24-48 hours after symptoms and fever have subsided. If used in streptococcal infections, therapy should be continued for 10 days to prevent the development of rheumatic fever or glomerulonephritis.

For children over 12 years of age, the recommended dosage schedule for those under 50 kg is 4 mg/kg on the first day and 2 mg/kg daily subsequently. For children over 50 kg the usual adult dose is used.

For the treatment of acne vulgaris the recommended dose is 50 mg of doxycycline taken daily with food, for up to 12 weeks.

In the treatment of acute gonococcal anterior urethritis in males, administer either: 200 mg stat and 100 mg at bedtime on the first day followed by 100 mg twice daily for 3-7 days, or 300 mg stat followed by 300 mg one hour later. For acute gonococcal infections in females use 200 mg twice daily.

When treating uncomplicated urethral, endocervical or rectal infection in adults caused by chlamydia trachomatis, give 100 mg twice daily for at least 7 days. The treatment of primary or secondary syphilis requires 300 mg daily in divided doses for at least 10 days.

In all cases DOXY should be administered with adequate amounts of fluid or food and the patient should remain sitting or standing for up to 2 hours afterwards to prevent the possible development of oesophageal irritation.

**Overdosage**

**Symptoms**

No reports of overdosage have been received.

**Management**

If such a case occurs, treatment requires discontinuation of DOXY and use of symptomatic treatment measures.
Presentation and Storage conditions

DOXY-50 tablets: white, film coated, circular biconvex tablet, having a diameter of approximately 6.3 mm.

DOXY-100 tablets: white, film-coated, circular, biconvex tablets scored on one side and having a diameter of 8 mm.

Storage

Protect from light and moisture.

DOXY-50 Tablets: Shelf life of 2 years (bottle) and 3 years (blister), store below 30 °C.

DOXY-100 Tablets: Shelf life of 2 years, store below 30 °C.

Pack quantities

DOXY-50 tablets: bottles containing 30 tablets; calendar packs containing 30 tablets.

DOXY-100 tablets: bottles containing 100 tablets.

Medicine Classification

Prescription Only Medicine.

Name and Address of Sponsor

Douglas Pharmaceuticals Ltd
P O Box 45 027
Auckland 0651
New Zealand

Phone:(09) 835 0660
Fax: (09) 835 0665

Date of Preparation

29 June 2015